30 October 2019 News
Sanofi and Regeneron have received the European Commission (EC) approval for Dupixent (dupilumab) to treat adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP).
29 October 2019 Sponsored
Allergic rhinitis (AR) is a chronic inflammatory disease that affects the nasal mucosa. The condition is caused by immunoglobin E (IgE) – mediated early-phase and late-phase hypersensitivity responses. Common symptoms...
24 October 2019 Analysis
Four years after Orkambi was approved in the European Union, this life-saving drug will now be available to Cystic Fibrosis (CF) patients in England through the NHS. The reason for...
7 October 2019 News
The US Food and Drug Administration (FDA) has approved self-administration AstraZeneca's asthma drug Fasenra, a pre-filled, single-use auto-injector.
25 September 2019 News
Bayer has committed more than $30m over the next five years to support research projects on therapies for chronic lung diseases at a joint lab in the US.
20 September 2019 Research Reports
Nursing home population in the 7MM, a high risk group for RSV infections, set to grow by 24% to 6.2m people by 2028, says GlobalData
Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus which belongs to the bigger family of Paramyxoviridae. This disease has only been public knowledge since 1956, when...
17 September 2019 Comment
There are at least 215 possible cases across 25 states where the development of severe lung disease has been linked to vaping.
13 September 2019 News
GlaxoSmithKline (GSK) has received the approval of the US Food and Drug Administration (FDA) for its Nucala (mepolizumab) drug to treat severe eosinophilic asthma in children aged 6-11 years.
12 September 2019 News
Vertex Pharmaceuticals has announced two of its cystic fibrosis (CF) drugs, Orkambi (lumacaftor-ivacaftor) and Symkevi (tezacaftor/ivacaftor) will now be available to eligible patients in Scotland through the National Health Service...
10 September 2019 News
The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Ofev (nintedanib) medicine to slow the rate of pulmonary function decline in systemic sclerosis-associated interstitial lung disease (SSc-ILD) patients.